ÂÜÀòÂÒÂ×

David I. Lichter is currently the Executive Director at Seres Therapeutics, leading the clinical research and science programs for SER-155, SER-287, and SER-301. Prior to this, David I. held positions at Lock Horns LLC, Leica Biosystems, and Millennium: The Takeda Oncology Company, where David I. focused on clinical research, assay development, and biomarker analysis. David holds a Bachelor of Science in Cell & Developmental Biology and an ALM in Biotechnology from Harvard University and University of Rochester, respectively.